Hepatology International

, Volume 5, Issue 2, pp 664–670

A comparison of 48-week treatment efficacy between clevudine and entecavir in treatment-naïve patients with chronic hepatitis B

  • Su Rin Shin
  • Byung Chul Yoo
  • Moon Seok Choi
  • Dong Ho Lee
  • Soon Mi Song
  • Joon Hyoek Lee
  • Kwang Cheol Koh
  • Seung Woon Paik
Original Article

DOI: 10.1007/s12072-010-9238-7

Cite this article as:
Shin, S.R., Yoo, B.C., Choi, M.S. et al. Hepatol Int (2011) 5: 664. doi:10.1007/s12072-010-9238-7

Abstract

Purpose

Clevudine and entecavir are currently available in Korea as antiviral drugs against chronic hepatitis B (CHB). We aimed to compare the efficacy of clevudine and entecavir therapy.

Methods

Treatment-naïve CHB patients who received 30 mg of clevudine or 0.5 mg of entecavir a day were analyzed. Mean reduction of hepatitis B virus (HBV) DNA levels, complete virological response (cVR, undetectable HBV DNA by real-time PCR), biochemical response (recovery to normal ALT level), and hepatitis B e antigen (HBeAg) seroconversion rate at the 48th week of treatment were assessed.

Results

A number of 59 patients in clevudine group and 61 patients in entecavir group were included. Mean HBV DNA reductions from baseline were similar in the clevudine and entecavir groups, −6.4 versus −6.8 log10 copies/mL in HBeAg-positive (p = 0.417) and −6.9 versus −7.0 log10 copies/mL in HBeAg-negative patients (p = 0.640). The proportion of patients who achieved cVR was not different between the two groups, 53 versus 55% in HBeAg-positive (p = 1.000) and 100 versus 95% in HBeAg-negative patients (p = 0.452). Biochemical response rates and HBeAg seroconversion rates were also similar in both the groups. Two (3.4%) patients in clevudine group showed virologic breakthrough with rtM204I mutation using direct sequencing analysis. Clinical myopathy occurred in two (3.4%) patients in clevudine group.

Conclusion

Mean reduction of viral loads was similar between clevudine and entecavir groups during 48 weeks. However, virologic breakthrough and significant myopathy were noted only in clevudine-treated patients. Therefore, more attention should be paid to patients receiving clevudine.

Keywords

Hepatitis B virusClevudineEntecavir

Copyright information

© Asian Pacific Association for the Study of the Liver 2010

Authors and Affiliations

  • Su Rin Shin
    • 1
  • Byung Chul Yoo
    • 2
  • Moon Seok Choi
    • 2
  • Dong Ho Lee
    • 3
  • Soon Mi Song
    • 3
  • Joon Hyoek Lee
    • 2
  • Kwang Cheol Koh
    • 2
  • Seung Woon Paik
    • 2
  1. 1.Department of Medicine, Kangnam Sacred Heart HospitalHallym UniversitySeoulKorea
  2. 2.Department of Medicine, Samsung Medical CentreSungkyunkwan University School of MedicineSeoulKorea
  3. 3.Digestive Disease Research CentreSamsung Medical CentreSeoulKorea